Search - tctmd.com

Displaying 221 - 240 of 300

Sort: Relevancy | Date

News Conference News ACC 2017

More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease

Yael L. Maxwell

March 09, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Daily News

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

Michael O'Riordan

January 05, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Daily News

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Michael O'Riordan

December 09, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Conference News AHA 2016

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

L.A. McKeown

November 17, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

AHA 提供他汀类药物和心血管药物药物相互作用指导

Michael O'Riordan

October 18, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

Advertisement

More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular News and Features for 2016

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

AHA 提供他汀类药物和心血管药物药物相互作用指导

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content